These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 34179347)
1. Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. Adhikary P; Kandel S; Mamani UF; Mustafa B; Hao S; Qiu J; Fetse J; Liu Y; Ibrahim NM; Li Y; Lin CY; Omoscharka E; Cheng K Adv Ther (Weinh); 2021 Jul; 4(7):2100087. PubMed ID: 34179347 [TBL] [Abstract][Full Text] [Related]
2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996 [TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
4. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy. Zeng X; Li L; Lin J; Li X; Liu B; Kong Y; Zeng S; Du J; Xiao H; Zhang T; Zhang S; Liu J Antib Ther; 2020 Apr; 3(2):95-100. PubMed ID: 33912790 [TBL] [Abstract][Full Text] [Related]
5. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK mBio; 2020 Dec; 11(6):. PubMed ID: 33310780 [TBL] [Abstract][Full Text] [Related]
6. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2. Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054 [TBL] [Abstract][Full Text] [Related]
7. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
8. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234 [TBL] [Abstract][Full Text] [Related]
9. Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors. Sarma S; Herrera SM; Xiao X; Hudalla GA; Hall CK J Phys Chem B; 2022 Oct; 126(41):8129-8139. PubMed ID: 36219223 [TBL] [Abstract][Full Text] [Related]
10. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169 [TBL] [Abstract][Full Text] [Related]
11. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
12. Penta-peptide ATN-161 based neutralization mechanism of SARS-CoV-2 spike protein. Rabbani G; Ahn SN; Kwon H; Ahmad K; Choi I Biochem Biophys Rep; 2021 Dec; 28():101170. PubMed ID: 34778573 [TBL] [Abstract][Full Text] [Related]
13. Preventive treatment of coronavirus disease-2019 virus using coronavirus disease-2019-receptor-binding domain 1C aptamer by suppress the expression of angiotensin-converting enzyme 2 receptor. Hameed NS; Arif IS; Al-Sudani BT J Adv Pharm Technol Res; 2023; 14(3):185-190. PubMed ID: 37692001 [TBL] [Abstract][Full Text] [Related]
15. Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2. Rathod SB; Prajapati PB; Punjabi LB; Prajapati KN; Chauhan N; Mansuri MF In Silico Pharmacol; 2020; 8(1):3. PubMed ID: 33184600 [TBL] [Abstract][Full Text] [Related]
16. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective. Borkotoky S; Dey D; Hazarika Z Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937 [TBL] [Abstract][Full Text] [Related]
17. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175 [TBL] [Abstract][Full Text] [Related]
18. Use of recombinant S1 protein with hFc for analysis of SARS-CoV-2 adsorption and evaluation of drugs that inhibit entry into VERO E6 cells. Couto JCM; Vidal T; Decker ER; Santurio JM; Mello CF; Pillat MM Immunol Lett; 2023 Nov; 263():105-112. PubMed ID: 37683695 [TBL] [Abstract][Full Text] [Related]
19. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A Molecules; 2021 May; 26(11):. PubMed ID: 34072087 [TBL] [Abstract][Full Text] [Related]
20. Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2. Lai YC; Cheng YW; Chao CH; Chang YY; Chen CD; Tsai WJ; Wang S; Lin YS; Chang CP; Chuang WJ; Chen LY; Wang YR; Chang SY; Huang W; Wang JR; Tseng CK; Lin CK; Chuang YC; Yeh TM Front Immunol; 2022; 13():868724. PubMed ID: 35603169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]